Placebo Controlled Study of Atomoxetine in the Treatment of Mild to Moderate Cognitive Difficulties in Menopausal Women

NACompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
MenopauseCognitive Disturbances
Interventions
DRUG

atomoxetine

Subjects will receive ATX 40mg/d x 1 week, then 80mg/d x 5 weeks followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week.

DRUG

placebo

Subjects will receive placebo equivalent for 6 weeks followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week.

Trial Locations (1)

06511

Yale University School of Medicine, New Haven

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

University of Pennsylvania

OTHER

NCT00611533 - Placebo Controlled Study of Atomoxetine in the Treatment of Mild to Moderate Cognitive Difficulties in Menopausal Women | Biotech Hunter | Biotech Hunter